Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial Bagot, M., Kim, Y., Zinzani, P., Dalle, S., Beylot-Barry, M., Ortiz-Romero, P. L., Cambalia, A., Dereure, O., Mortier, L., Jacobsen, E., Battistella, M., Gru, A., Moins-Teisserenc, H., Paiva, C., Boyer-Chammard, A., Rotolo, F., Azim, H. A., Porcu, P. ELSEVIER SCI LTD. 2021: S20-S21
View details for Web of Science ID 000719152800039